Bushnell DL - Search Results

1

Overview and Current Status of Peptide Receptor Radionuclide Therapy.

Bushnell DL, Bodeker KL. Bushnell DL, et al. Surg Oncol Clin N Am. 2020 Apr;29(2):317-326. doi: 10.1016/j.soc.2019.11.005. Surg Oncol Clin N Am. 2020. PMID: 32151363 Review.

2

Addition of ¹³¹I-MIBG to PRRT (⁹⁰Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors.

Bushnell DL, Bodeker KL, O'Dorisio TM, Madsen MT, Menda Y, Graves S, Zamba GKD, O'Dorisio MS. Bushnell DL, et al. J Nucl Med. 2021 Sep 1;62(9):1274-1277. doi: 10.2967/jnumed.120.254987. Epub 2021 Jan 30. J Nucl Med. 2021. PMID: 33517327 Free PMC article.

3

Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.

Sharma N, Naraev BG, Engelman EG, Zimmerman MB, Bushnell DL Jr, OʼDorisio TM, OʼDorisio MS, Menda Y, Müller-Brand J, Howe JR, Halfdanarson TR. Sharma N, et al. Among authors: bushnell dl jr. Pancreas. 2017 Feb;46(2):151-156. doi: 10.1097/MPA.0000000000000734. Pancreas. 2017. PMID: 27759712 Free PMC article.

4

⁹⁰Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.

Menda Y, Madsen MT, O'Dorisio TM, Sunderland JJ, Watkins GL, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS. Menda Y, et al. Among authors: bushnell dl. J Nucl Med. 2018 Nov;59(11):1692-1698. doi: 10.2967/jnumed.117.202903. Epub 2018 Mar 9. J Nucl Med. 2018. PMID: 29523629 Free PMC article. Clinical Trial.

5

NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE.

Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, Lindsay S, Metz DC, Pryma DA, Stabin MG, Strosberg JR. Hope TA, et al. Among authors: bushnell dl. J Nucl Med. 2019 Jul;60(7):937-943. doi: 10.2967/jnumed.118.230607. J Nucl Med. 2019. PMID: 31263080 Free article.

6

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.

Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. Love C, et al. Among authors: bushnell dl. Am J Clin Oncol. 2022 Jun 1;45(6):233-242. doi: 10.1097/COC.0000000000000903. Epub 2022 May 4. Am J Clin Oncol. 2022. PMID: 35507413

7

Standard imaging techniques for neuroendocrine tumors.

Bushnell DL, Baum RP. Bushnell DL, et al. Endocrinol Metab Clin North Am. 2011 Mar;40(1):153-62, ix. doi: 10.1016/j.ecl.2010.12.002. Endocrinol Metab Clin North Am. 2011. PMID: 21349416 Review.

8

Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors.

Khanna G, Bushnell D, O'Dorisio MS. Khanna G, et al. Oncologist. 2008 Apr;13(4):382-9. doi: 10.1634/theoncologist.2007-0175. Oncologist. 2008. PMID: 18448552 Free article. Review.

9

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.

Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. Love C, et al. Among authors: bushnell dl. Clin Nucl Med. 2022 Jun 1;47(6):503-511. doi: 10.1097/RLU.0000000000004182. Clin Nucl Med. 2022. PMID: 35507433

10

Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors.

Bushnell D. Bushnell D. J Gastrointest Surg. 2006 Mar;10(3):335-6. doi: 10.1016/j.gassur.2005.08.025. J Gastrointest Surg. 2006. PMID: 16622984 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

92 results

Search Page